» Articles » PMID: 16106528

A Motor Function Measure for Neuromuscular Diseases. Construction and Validation Study

Overview
Specialty Neurology
Date 2005 Aug 18
PMID 16106528
Citations 128
Authors
Affiliations
Soon will be listed here.
Abstract

A new scale for motor function measurement has been developed for neuromuscular diseases. The validation study included 303 patients, aged 6-62 years. Seventy-two patients had Duchenne muscular dystrophy, 32 Becker muscular dystrophy, 30 limb-girdle muscular dystrophy, 39 facio-scapulo-humeral dystrophy, 29 myotonic dystrophy, 21 congenital myopathy, 10 congenital muscular dystrophy, 35 spinal muscular atrophy and 35 hereditary neuropathy. The scale comprised 32 items, in three dimensions: standing position and transfers, axial and proximal motor function, distal motor function. Agreement coefficients for inter-rater reliability were excellent (kappa=0.81-0.94) for nine items, good (kappa=0.61-0.80) for 20 items and moderate (kappa=0.51-0.60) for three items. High correlations were found between the total score and other scores: Vignos (r=0.91) and Brooke (r=0.85) grades, Functional Independence Measure (r=0.91), the global severity of disability evaluated with visual analog scales by physicians (r=0.88) and physiotherapists (r=0.91). This scale is reliable, does not require any special equipment and is well-accepted by patients. Its sensitivity to change is being assessed to permit its use in clinical trials of neuromuscular diseases.

Citing Articles

Use of assistive technology to assess distal motor function in subjects with neuromuscular disease.

Vincent-Genod D, Roche S, Barriere A, de Lattre C, Tinat M, Venema E PLOS Digit Health. 2025; 4(1):e0000534.

PMID: 39804823 PMC: 11729976. DOI: 10.1371/journal.pdig.0000534.


Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy.

Kesenheimer E, Wendebourg M, Weidensteiner C, Sander L, Weigel M, Haas T J Neurol. 2025; 272(1):102.

PMID: 39775109 PMC: 11706851. DOI: 10.1007/s00415-024-12740-3.


A 5-year natural history cohort of patients with facioscapulohumeral muscular dystrophy determining disease progression and feasibility of clinical outcome assessments for clinical trials.

Kools J, Vincenten S, van Engelen B, Voet N, Merkies I, Horlings C Muscle Nerve. 2024; 71(1):55-62.

PMID: 39508285 PMC: 11632561. DOI: 10.1002/mus.28293.


A 5-year natural history study in LAMA2-related muscular dystrophy and SELENON-related myopathy: the Extended LAST STRONG study.

de Laat E, Houwen-van Opstal S, Bouman K, van Doorn J, Cameron D, van Alfen N BMC Neurol. 2024; 24(1):409.

PMID: 39443859 PMC: 11515704. DOI: 10.1186/s12883-024-03852-4.


Cultural adaptation, validity and reliability of the Turkish version of north star ambulatory assessment.

Aydin-Yagcioglu G, Bulut N, Ugur F, Yilmaz O, Alemdaroglu-Gurbuz I Acta Neurol Belg. 2024; 125(1):127-132.

PMID: 39436553 DOI: 10.1007/s13760-024-02670-2.